A new study in human and mouse cell lines shows that specific proteins that have long been studied as inhibitors of influenza can also inhibit SARS-CoV-2, the type of coronavirus that causes COVID-19.
The genetically altered yellow fever vaccine was highly effective in animals. If it passes clinical trials, the new vaccine would have some advantages over other SARS-CoV-2 vaccines.
A nasal spray called KEPTIDE may work to prevent COVID-19 by stopping the virus from attaching onto and entering cells.
Researches at Washington State University created a new method of therapeutic delivery for COVID-19, using human white blood cell membranes to carry an antibiotic and an anti-inflammatory directly to the lungs of mice that had an infection.
Two teams from City of Hope and Canadian biotech Biovaxys Technology have reported positive data for their investigational COVID-19 vaccine products in animals. The two products, based on vaccine platforms that are different from the mRNA technology, are designed to induce both antibody and T-cell immunity.
Researchers report that their LEAPS COV-19 peptides significantly improved survival in a murine model of COVID-19.
Administering two doses of a COVID-19 vaccine called BVX-0320 is effective in mouse models, a pre-clinical study has shown.
A repurposed mouse model can develop symptoms of both severe COVID-19 (lung damage, blood clots, abnormal blood vessels, and death) and also of milder disease, including loss of the sense of smell, according to a recent study.
A recently created therapy for the influenza virus may help aid in the fight against COVID-19.
A pre-engineered version of Adagio’s lead drug candidate, ADG20, protected against SARS-CoV and SARS-CoV-2—the virus that causes COVID-19—in mouse models. In lab tests, the drug also neutralized WIV-1 and SHC014, two related coronaviruses known to be circulating in bats.
Immunologists have determined the process driving life-threatening inflammation, lung damage and organ failure in patients with COVID-19, sepsis and other inflammatory disorders suggesting possible treatment using existing drugs.
The Moderna vaccine is 94.5% effective against coronavirus, according to early data released Monday by the company, making it the second vaccine in the United States to have a stunningly high success rate.
Pfizer said Monday that early results from its coronavirus vaccine suggest the shots may be a surprisingly robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration.
COVID-19 vaccine testing has begun in Vietnam on monkeys, according to the Company for Vaccine and Biological Production (Vabiotech) under the country's Ministry of Health.
Icosovax is turning its virus-like particle (VLP) technology to fight COVID-19 with help from $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.
Researchers in Iowa are developing a vaccine to fight the COVID-19 pandemic with unique attributes: it's synthetic, stable at room temperature — for up to a year — and can be administered through an inhaler or nasal spray without a medical professional present.
A study in mice hints at drugs that could be helpful in treating severe coronavirus infections
Preclinical data published in Cell show the nanoparticle vaccine spurs extremely high levels of protective antibodies in animal models.
Moderna and Pfizer may be considered the front-runners in the effort to develop mRNA vaccines against COVID-19, but they’re not the only contenders in that race. Sanofi and its partner Translate Bio have also been working on a vaccine that uses mRNA to prompt an immune response—and now they have animal data that they believe provide strong backing for the phase 1/2 trial expected to start this quarter.
COVID-19 poses the greatest threat to older people, but vaccines often don’t work well in this group. Scientists hope drugs that rejuvenate the immune system will help.
Developed by Altimmune Inc., the vaccine called AdCOVID is administered by a single intranasal spray. The biopharmaceutical company, which published its pre-clinical findings on the open-source preprint server bioRxiv*, highlights the efficacy of its intranasal COVID-19 vaccine candidate.
Virologists at the Rega Institute have shown that the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters. A high dose of the anti-flu drug favipiravir, by contrast, has an antiviral effect in the hamsters.
Researchers have found that an effective way of treating the coronavirus behind the 2003 SARS epidemic also works on the closely related SARS-CoV-2 virus, the culprit in the ongoing COVID-19 pandemic. The substance concerned is nitric oxide (NO), a compound with antiviral properties that is produced by the body itself.
Coronavirus treatments will be key to getting back to normal, even with a vaccine.
A Chinese drugmaker, which is collaborating with AstraZeneca PLC on production of a coronavirus vaccine, has won approval from Chinese regulators to start testing one of its own vaccine candidates at home.
